TRANSLATIONAL CANCER RESEARCH
主办单位:AME Publishing Company
出版周期:
未知
语种:英文
国际刊号:2218-676X
期刊预警:
不在预警名单中
投稿经验(3)
医脉通用户3960084
2021-12-28 00:22:06
总的来说,投稿过程挺漫长的。审稿人意见等了两个多月,但是给的意见很中肯。
医脉通用户9860521
2021-06-08 07:38:27
审稿速度为1个月 投稿是否录用直接录用 
投了好几篇都录用了,但不是核心期刊,只是国家级医学期刊,对有核心期刊要求的就不推荐了哈。
医脉通用户9652564
2020-05-26 06:42:47
杂志不错,审稿人很负责人,提了不少很专业的意见,对改善论文可读性非常有帮助。
发布我的投稿经验
刊物简介
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.